Compare Devon Energy Corp (DVN) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Devon Energy Corp vs Organon & Co. Common Stock — how do they compare? Devon Energy Corp trades at $50.29 (market cap $55.23B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Devon Energy Corp is far larger — about 15.3× Organon & Co. Common Stock's market cap, and Devon Energy Corp pays the higher dividend (2.55%). Which is the better fit depends on your goals — on Pluang, investors hold Devon Energy Corp for 136 Days and Organon & Co. Common Stock for 0 Days on average.
| DVN | OGN | |
|---|---|---|
Market Cap | $55.23B | $3.62B |
Volume | 10,032,111 | 2,892,999 |
Sector | Energy | Health |
52-Week High | $52.07 | $13.81 |
52-Week Low | $31.74 | $5.70 |
Typical Hold Time | 136 Days | 0 Days |
Enterprise Value | $65.97B | $11.04B |
Dividend Yield | 2.55% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Devon Energy (DVN) trades at $49.92, up 1.96% with strong bullish technical signals from moving averages. The stock shows attractive valuation metrics including a P/E of 10.92 and P/S of 1.79, while maintaining solid profitability with 16.67% net margins. Recent activist investor pressure for strategic alternatives and potential asset sales create catalysts, though the company faces earnings volatility with mixed quarterly results including a Q1 miss but Q2 beat.
DVN presents value opportunity with 25% upside to consensus target of $62.53, supported by 72% analyst buy ratings. Key risks include oil price sensitivity and execution on asset sales, while the improving cash flow trend and Permian Basin focus provide fundamental support. The combination of reasonable valuation and strategic optionality makes DVN compelling for energy investors.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Devon Energy Corp
Devon Energy, based in Oklahoma City, is one of the largest independent exploration and production companies in North America. The firm's asset base is spread throughout onshore North America and includes exposure to the Delaware, STACK, Eagle Ford, Powder River Basin, and Bakken plays. At year-end 2021, Devon's proved reserves totaled 1.6 billion barrels of oil equivalent, and net production that year was 572 thousand boe/d, of which oil and natural gas liquids made up 74% of production, with natural gas accounting for the remainder.
Read more on DVN →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
